193 related articles for article (PubMed ID: 37583901)
1. The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19.
Xia B; Zheng L; Li Y; Sun W; Liu Y; Li L; Pang J; Chen J; Li J; Cheng H
Front Pharmacol; 2023; 14():1098972. PubMed ID: 37583901
[TBL] [Abstract][Full Text] [Related]
2. Cepharanthine: A Promising Old Drug against SARS-CoV-2.
Fan H; He ST; Han P; Hong B; Liu K; Li M; Wang S; Tong Y
Adv Biol (Weinh); 2022 Dec; 6(12):e2200148. PubMed ID: 35775953
[TBL] [Abstract][Full Text] [Related]
3. Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19.
Rogosnitzky M; Okediji P; Koman I
Pharmacol Rep; 2020 Dec; 72(6):1509-1516. PubMed ID: 32700247
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus.
Li S; Liu W; Chen Y; Wang L; An W; An X; Song L; Tong Y; Fan H; Lu C
Brief Bioinform; 2021 Mar; 22(2):1378-1386. PubMed ID: 33423067
[TBL] [Abstract][Full Text] [Related]
5. [Progress in the study of antiviral activity of cepharanthine against SARS-CoV-2].
Fan H; Liu K; Hong B; He S; Han P; Li M; Wang S; Tong Y
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):955-956. PubMed ID: 35790449
[TBL] [Abstract][Full Text] [Related]
6. Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2.
Hijikata A; Shionyu-Mitsuyama C; Nakae S; Shionyu M; Ota M; Kanaya S; Hirokawa T; Nakajima S; Watashi K; Shirai T
FEBS Open Bio; 2022 Jan; 12(1):285-294. PubMed ID: 34850606
[TBL] [Abstract][Full Text] [Related]
7. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.
Yin J; Li C; Ye C; Ruan Z; Liang Y; Li Y; Wu J; Luo Z
Comput Struct Biotechnol J; 2022; 20():824-837. PubMed ID: 35126885
[TBL] [Abstract][Full Text] [Related]
8. Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury.
Liang D; Wang W; Chen G; Li J; Dou G; Gan H; Han P; Du L; Gu R
Molecules; 2023 May; 28(11):. PubMed ID: 37298919
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the mechanism of action of cepharanthine for the treatment of novel coronavirus pneumonia (COVID-19) from the perspectives of systematic pharmacology.
Sun F; Liu J; Tariq A; Wang Z; Wu Y; Li L
Arab J Chem; 2023 Jun; 16(6):104722. PubMed ID: 36910427
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Activity of Cepharanthine.
Liu K; Hong B; Wang S; Lou F; You Y; Hu R; Shafqat A; Fan H; Tong Y
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446681
[TBL] [Abstract][Full Text] [Related]
11. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.
Ohashi H; Watashi K; Saso W; Shionoya K; Iwanami S; Hirokawa T; Shirai T; Kanaya S; Ito Y; Kim KS; Nomura T; Suzuki T; Nishioka K; Ando S; Ejima K; Koizumi Y; Tanaka T; Aoki S; Kuramochi K; Suzuki T; Hashiguchi T; Maenaka K; Matano T; Muramatsu M; Saijo M; Aihara K; Iwami S; Takeda M; McKeating JA; Wakita T
iScience; 2021 Apr; 24(4):102367. PubMed ID: 33817567
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.
Lawal B; Kuo YC; Rachmawati Sumitra M; Wu ATH; Huang HS
Comput Biol Med; 2022 Sep; 148():105814. PubMed ID: 35841781
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
Forte-Soto P; Albayaty M; Brooks D; Arends RH; Tillinghast J; Aksyuk AA; Bouquet J; Chen C; Gebre A; Kubiak RJ; Pilla Reddy V; Seegobin S; Streicher K; Templeton A; Esser MT
J Infect Dis; 2023 May; 227(10):1153-1163. PubMed ID: 36683419
[TBL] [Abstract][Full Text] [Related]
14. Antiviral effects of phytochemicals against severe acute respiratory syndrome coronavirus 2 and their mechanisms of action: A review.
Jantan I; Arshad L; Septama AW; Haque MA; Mohamed-Hussein ZA; Govender NT
Phytother Res; 2023 Mar; 37(3):1036-1056. PubMed ID: 36343627
[TBL] [Abstract][Full Text] [Related]
15. Current status and future challenges in extraction, purification and identification of Cepharanthine (a potential drug against COVID-19).
Wang Y; Zhou X; Wei S; Wang G; Xi J
Sep Purif Technol; 2023 Mar; 309():123038. PubMed ID: 36593875
[TBL] [Abstract][Full Text] [Related]
16. Polyphenols as promising biologically active substances for preventing SARS-CoV-2: A review with research evidence and underlying mechanisms.
Mehany T; Khalifa I; Barakat H; Althwab SA; Alharbi YM; El-Sohaimy S
Food Biosci; 2021 Apr; 40():100891. PubMed ID: 33495727
[TBL] [Abstract][Full Text] [Related]
17. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
18. Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir "S-217622": A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species.
Eltayb WA; Abdalla M; Rabie AM
ACS Omega; 2023 Feb; 8(6):5234-5246. PubMed ID: 36798145
[TBL] [Abstract][Full Text] [Related]
19. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
20. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
